SEARCH

SEARCH BY CITATION

References

  • Al-Shami, A., Mahanna, W. & Naccache, P.H. (1998) Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. Journal of Biological Chemistry, 273, 10581063.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Florensa, L., Besses, C., Zamora, L., Bellosillo, B., Espinet, B., Serrano, S., Woessner, S. & Sole, F. (2004) Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood, 103, 24272428.
  • Goerttler, P.S., Steimle, C., Marz, E., Johansson, P.L., Andreasson, B., Griesshammer, M., Gisslinger, H., Heimpel, H. & Pahl, H.L. (2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood, doi: 10.1182/blood-2005–04–1515. Prepublished online 28 June 2005.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds) (2001) WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. IARC Press, Lyon.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 434, 11441148.
  • Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H.M. & Issa, J.P. (2005) JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood, doi: 10.1182/blood-2005–05–1800. Prepublished online 21 July 2005.
  • Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlman, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C.P. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, doi: 10·1182/blood-2005–03–1320. Prepublished online 26 May 2005.
  • Klippel, S., Strunck, E., Temerinac, S., Bench, A.J., Meinhardt, G., Mohr, U., Leichtel, R., Green, A.R., Greisshammer, M., Heimpel, H. & Pahl, H.L. (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood, 102, 35693574.
  • Koch, C.A., Lasho, T.L. & Tefferi, A. (2004) Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology, 127, 3439.
  • Kralovics, R., Buser, A.S., Teo, S.S., Coers, J., Tichelli, A., van der Maas, A.P. & Skoda, R.C. (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood, 102, 18691871.
  • Kralovics, R., Passamonti, F., Buser, A.S., Soon-Siong, T., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 17791790.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Liu, E., Jelinek, J., Pastore, Y.D., Guan, Y., Prchal, J.F. & Prchal, J.T. (2003) Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood, 101, 32943301.
  • Ma, D.D., Wei, A.Q., Dowton, L.A., Lau, K.S., Wu, Z.H. & Ueda, M. (1992) Assessment of an EIA for measuring human serum erythropoietin as compared with RIA and an in-vitro bioassay. British Journal of Haematology, 80, 431436.
  • Moliterno, A.R., Hankins, W.D. & Spivak, J.L. (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. New England Journal of Medicine, 338, 572580.
  • Mossuz, P., Girodon, F., Donnard, M., Latger-Cannard, V., Dobo, I., Boiret, N., Lecron, J.C., Binquet, C., Barro, C., Hermouet, S. & Praloran, V. (2004) Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica, 89, 11941198.
  • Passamonti, F., Pietra, D., Malabarba, L., Rumi, E., Della Porta, M.G., Malcovati, L., Bonfichi, M., Pascutto, C., Lazzarino, M. & Cazzola, M. (2004) Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 126, 650656.
  • Reid, C.D. (1987) The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Reviews, 1, 133140.
  • Sirhan, S., Lasho, T.L., Elliott, M.A. & Tefferi, A. (2005) Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates. Haematologica, 90, 406408.
  • Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. & Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘‘atypical’’ myeloproliferative disorders and the myelodysplastic syndrome. Blood, 106, 12071209.
  • Tefferi, A., Yoon, S.Y. & Li, C.Y. (2000) Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood, 96, 771772.
  • Tefferi, A., Lasho, T.L., Wolanskyj, A.P. & Mesa, R.A. (2004) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood, 103, 35473548.
  • Tefferi, A., Lasho, T.L., Gilliland, D.G. & Dewald, G. (2005) Is homozygosity for JAK2 V617F in myeloproliferative disorders a time-acquired phenomenon?. New England Journal of Medicine (in press).
  • Temerinac, S., Klippel, S., Strunck, E., Roder, S., Lubbert, M., Lange, W., Azemar, M., Meinhardt, G., Schaefer, H.E. & Pahl, H.L. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood, 95, 25692576.
  • Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., Mcclure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. & Tefferi, A. (2005) JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology (in press).
  • Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 2278822792.